Hudson Bay Capital Management
EPRX

Hudson Bay Capital Management’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Hudson Bay Capital Management’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-92,347
Closed -$669K – 1742
2026
Q1 		$669K Buy
+92,347
New +$743K ﹤0.01% 941

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Hudson Bay Capital Management's EPRX Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Eupraxia Pharmaceuticals (EPRX) in Q2 2026, closing a stake of 92,347 shares — an estimated $669K sold.

Hudson Bay Capital Management first reported a position in EPRX in Q1 2026 and held it in 1 quarter. The position peaked at $669K in Q1 2026. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Eupraxia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 92,347 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $669K.
  • Hudson Bay Capital Management first reported a position in Eupraxia Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Hudson Bay Capital Management's Eupraxia Pharmaceuticals position peaked at $669K in Q1 2026.
  • 67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.